BMRA · NASDAQ
Biomerica (BMRA) Stock Price & Fundamentals
Biomerica (BMRA) closed at $651.33 on Oct 9, 2026, up 1.02% from the previous close of $644.78.
Share price, past year
1Y +32.18%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $651.33 |
| Sep 30, 2026 | $637.48 |
| Aug 31, 2026 | $624.27 |
| Jul 31, 2026 | $576.24 |
| Jun 30, 2026 | $578.75 |
| May 29, 2026 | $539.89 |
| Apr 30, 2026 | $510.14 |
| Mar 31, 2026 | $502.81 |
| Feb 27, 2026 | $490.82 |
| Jan 30, 2026 | $482.96 |
| Dec 31, 2025 | $512.31 |
| Nov 28, 2025 | $513.88 |
| Oct 31, 2025 | $491.67 |
Key statistics
- Market cap
- $2.08B
- P/E (TTM)
- —
- EPS (TTM)
- −$1.30
- Revenue (TTM)
- $4.45M
- Net income (TTM)
- −$3.78M
- Shares outstanding
- 3.2M
- Dividend yield
- —
- 52-week range
- $478.83 – $651.33
Biomerica's market cap is $2.08B, based on a share price of $651.33 and 3.2M shares outstanding as of May 31, 2026.
Financials
Biomerica reported revenue of $4.45M for fiscal 2026, down 16.16% from fiscal 2025.
Biomerica reported a net loss of $3.78M in fiscal 2026.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2026ended May 31, 2026 | $4.45M | −16.2% | −$3.78M | −84.8% | −$1.30 | — |
| FY2025ended May 31, 2025 | $5.31M | −1.9% | −$4.97M | −93.6% | −$2.16 | — |
| FY2024ended May 31, 2024 | $5.42M | +1.4% | −$5.98M | −110.4% | −$2.84 | −$5.41M |
| FY2023ended May 31, 2023 | $5.34M | −71.7% | −$7.14M | −133.7% | −$0.50 | −$5.54M |
| FY2022ended May 31, 2022 | $18.87M | +162.1% | −$4.53M | −24.0% | −$0.36 | −$536.00K |
| FY2021ended May 31, 2021 | $7.20M | +7.6% | −$7.45M | −103.4% | −$0.62 | −$5.39M |
| FY2020ended May 31, 2020 | $6.69M | +28.7% | −$2.68M | −40.0% | −$0.26 | −$4.33M |
| FY2019ended May 31, 2019 | $5.20M | −6.5% | −$2.39M | −46.0% | −$0.26 | −$2.35M |
| FY2018ended May 31, 2018 | $5.56M | −3.9% | −$1.47M | −26.3% | −$0.17 | −$1.30M |
| FY2017ended May 31, 2017 | $5.79M | — | −$908.56K | −15.7% | −$0.11 | −$818.94K |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q4 FY2026ended May 31, 2026 | $876.00K | −$1.15M | −$0.41 |
| Q3 FY2026ended Feb 28, 2026 | $987.00K | −$1.31M | −$0.44 |
| Q2 FY2026ended Nov 30, 2025 | $1.21M | −$1.32M | −$0.45 |
| Q1 FY2026ended Aug 31, 2025 | $1.38M | $2.00K | $0.00 |
| Q4 FY2025ended May 31, 2025 | $749.00K | −$1.54M | −$0.99 |
| Q3 FY2025ended Feb 28, 2025 | $1.12M | −$1.16M | −$0.48 |
| Q2 FY2025ended Nov 30, 2024 | $1.64M | −$950.00K | −$0.06 |
| Q1 FY2025ended Aug 31, 2024 | $1.81M | −$1.32M | −$0.63 |
Company profile
- Name
- Biomerica, Inc.
- Ticker
- BMRA
- Exchange
- NASDAQ
- Industry (SEC SIC)
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- 17571 Von Karman Avenue, Irvine, CA 92614
- Incorporated in
- DE
- Fiscal year ends
- May
- SEC CIK
- 0000073290
Recent SEC filings
- Sep 28, 2026
- Aug 31, 2026
- Aug 26, 2026
- Jun 4, 2026
- Apr 13, 2026
- Jan 14, 2026
- Dec 16, 2025
- Oct 14, 2025
Frequently asked questions
What is Biomerica's stock price?
Biomerica (BMRA) closed at $651.33 on Oct 9, 2026, up 1.02% from the previous close of $644.78.
What is Biomerica's market cap?
Biomerica's market cap is $2.08B, based on a share price of $651.33 and 3.2M shares outstanding as of May 31, 2026.
How much revenue does Biomerica make?
Biomerica reported revenue of $4.45M for fiscal 2026, down 16.16% from fiscal 2025.
Does Biomerica pay a dividend?
Biomerica's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Biomerica, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures